| 词条 | Orexigen Therapeutics |
| 释义 |
| name = Orexigen Therapeutics, Inc. | logo = File:Logo_of_Orexigen_Therapeutics.jpg| | logo_size = | logo_alt = | logo_caption = | logo_padding = | image = | image_size = | image_alt = | image_caption = | native_name = | native_name_lang = | former_name = | type = Public | industry = | founded = {{start date|2002}} | founder = Eckard Weber | hq_location = La Jolla, California, U.S. | hq_location_city = | hq_location_country = | area_served = | key_people = | products = | brands = | services = | owner = | homepage = {{url|www.orexigen.com}} }} Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity.[1] The company is based in La Jolla, California and was established by Eckard Weber in 2002.[1] As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX.[1] The company has a single product, Contrave, approved for use in the United States in 2014. The launch of Contrave was conducted through a sales force of 900.[5]{{rs|date=June 2015}} Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.{{rs|date=June 2015}} References1. ^1 {{cite news | author=Osborne, Spencer | title=Contrave Sales Continue To Impress | date=12 December 2014 | work=Seeking Alpha | url=http://seekingalpha.com/article/2752575-contrave-sales-continue-to-impress }} [1][2]2. ^1 2 3 {{cite web |title=OREX Key Statistics |url=http://www.marketwatch.com/investing/stock/orex/profile |accessdate=12 September 2014 |website=MarketWatch |deadurl=no }} }}{{US-manufacturing-company-stub}} 5 : Health care companies based in California|Pharmaceutical companies established in 2002|Pharmaceutical companies of the United States|Companies listed on NASDAQ|2002 establishments in California |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。